Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$0.34.

  • Insight Molecular Diagnostics' EPS (Basic) rose 6530.61% to -$0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.88, marking a year-over-year increase of 4268.29%. This contributed to the annual value of -$4.67 for FY2024, which is 112111.54% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its EPS (Basic) stood at -$0.34 for Q3 2025, which was up 6530.61% from -$0.3 recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' EPS (Basic) peaked at $0.0 during Q1 2023, and registered a low of -$8.16 during Q4 2022.
  • Its 5-year average for EPS (Basic) is -$1.11, with a median of -$0.38 in 2021.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 10073.7% in 2023, then plummeted by 13752682.18% in 2024.
  • Insight Molecular Diagnostics' EPS (Basic) (Quarter) stood at -$0.4 in 2021, then plummeted by 1939.89% to -$8.16 in 2022, then soared by 90.07% to -$0.81 in 2023, then crashed by 217.63% to -$2.57 in 2024, then soared by 86.78% to -$0.34 in 2025.
  • Its EPS (Basic) was -$0.34 in Q3 2025, compared to -$0.3 in Q2 2025 and -$0.26 in Q1 2025.